Immunic announces vidofludimus calcium reduced risk of disability worsening by 30% in primary progressive multiple sclerosis patients from phase 2 calliper trial

– reduced relative risk of 24-week confirmed disability worsening events by 20% in overall study population compared to placebo; even more prominent 30% reduction in high unmet need population of primary progressive multiple sclerosis – – showed consistent reduction of disability worsening in subpopulations without inflammatory lesions at baseline in overall study population; reduced relative risk of 24-week confirmed disability worsening events in patients without gadolinium-enhancing lesions at baseline by 29% compared to placebo – – reduced annualized rate of thalamic brain volume loss by 20% compared to placebo – – confirmed favorable safety and tolerability observed in previous clinical trials; no new safety signals identified – – webcast to be held today, april 30, at 8:00 am et – new york , april 30, 2025 /prnewswire/ -- immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive data from its phase 2 calliper trial of nuclear receptor related 1 (nurr1) activator, vidofludimus calcium (imu-838), in patients with progressive multiple sclerosis (pms). clinical endpoints in the overall pms patient population (n=467), vidofludimus calcium reduced the relative risk of 24-week confirmed disability worsening (24wcdw) events based on changes in the expanded disability status scale (edss) by 20% compared to placebo.
IMUX Ratings Summary
IMUX Quant Ranking